Literature DB >> 17443125

Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray.

Carol S Myers1, Richard C Taylor, Eric T Moolchan, Stephen J Heishman.   

Abstract

The discovery of the role of nicotinic receptors in attention and memory has led to the testing of nicotinic analogs as cognitive enhancing agents in patient populations. Empirical information about nicotine's ability to enhance elements of attention and memory in normal individuals might guide development of therapeutic uses of nicotine in cognitively impaired populations. The purpose of this study was to determine the effect of nicotine on continuous attention, working memory, and computational processing in tobacco-deprived and nondeprived smokers. A total of 28 smokers (14 men, 14 women) participated in a double-blind, placebo-controlled, within-subject study, in which they were overnight (12 h) tobacco deprived at one session and smoked ad libitum before the other session. At each session, participants received 0, 1, and 2 mg nicotine via nasal spray in random order at 90 min intervals. Before and after each dose, a battery of cognitive, subjective, and physiological measures was administered, and blood samples were taken for plasma nicotine concentration. Overnight tobacco deprivation resulted in impaired functioning on all cognitive tests and increased self-reports of tobacco craving and negative mood; nicotine normalized these deficits. In the nondeprived condition, nicotine enhanced performance on the continuous performance test (CPT) and an arithmetic test in a dose-related manner, but had no effect on working memory. In general, women were more sensitive than men to the subjective effects of nicotine. These results provide an unequivocal determination that nicotine enhanced attentional and computational abilities in nondeprived smokers and suggest these cognitive domains as substrates for novel therapeutic indications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443125     DOI: 10.1038/sj.npp.1301425

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  71 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

3.  Chronic smoking, but not acute nicotine administration, modulates neural correlates of working memory.

Authors:  Matthew T Sutherland; Thomas J Ross; Diaá M Shakleya; Marilyn A Huestis; Elliot A Stein
Journal:  Psychopharmacology (Berl)       Date:  2010-09-23       Impact factor: 4.530

Review 4.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

5.  Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study.

Authors:  Rebecca L Ashare; Riju Ray; Caryn Lerman; Andrew A Strasser
Journal:  Drug Alcohol Depend       Date:  2012-05-15       Impact factor: 4.492

6.  Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies.

Authors:  Matthew T Sutherland; Kimberly L Ray; Michael C Riedel; Julio A Yanes; Elliot A Stein; Angela R Laird
Journal:  Biol Psychiatry       Date:  2015-01-07       Impact factor: 13.382

7.  Use of an automated mobile application to assess effects of nicotine withdrawal on verbal fluency: A pilot study.

Authors:  Serguei V S Pakhomov; Wrenda Teeple; Anne M Mills; Michael Kotlyar
Journal:  Exp Clin Psychopharmacol       Date:  2016-08-15       Impact factor: 3.157

8.  Cognitive deficits specific to depression-prone smokers during abstinence.

Authors:  Rebecca Ashare; Andrew A Strasser; E Paul Wileyto; Jocelyn Cuevas; Janet Audrain-McGovern
Journal:  Exp Clin Psychopharmacol       Date:  2014-06-16       Impact factor: 3.157

9.  Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study.

Authors:  Karen J Hartwell; Todd Lematty; Aimee L McRae-Clark; Kevin M Gray; Mark S George; Kathleen T Brady
Journal:  Am J Drug Alcohol Abuse       Date:  2013-03       Impact factor: 3.829

10.  Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients.

Authors:  L Elliot Hong; Ikwunga Wonodi; Jada Lewis; Gunvant K Thaker
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.